a Department of Hematology , National Cancer Center Hospital , Tokyo , Japan.
Expert Opin Biol Ther. 2019 Mar;19(3):197-209. doi: 10.1080/14712598.2019.1572746. Epub 2019 Jan 29.
Peripheral T-cell lymphoma (PTCL) is a relatively rare, heterogeneous group of mature T-cell neoplasms generally associated with poor prognosis, partly because of refractoriness against conventional cytotoxic chemotherapies. To improve the outcome of patients with PTCL, the clinical development of several novel agents is currently under investigation.
Since the first approval of pralatrexate (dihydrofolate reductase inhibitor) by the US Food and Drug Administration, belinostat, romidepsin (histone deacetylase inhibitors), and brentuximab vedotin (anti-CD30 antibody-drug conjugate) have been approved in the US, and many other countries. In addition, mogamulizumab (anti-CC chemokine receptor 4 antibody), chidamide (histone deacetylase inhibitor), and forodesine (purine nucleoside phosphorylase inhibitor) have been approved in Asian countries, including China, and Japan. In this review, we have summarized the available data regarding these approved agents and new agents currently under development for PTCL.
Novel agents will be a promising therapeutic option in selected patients with relapsed/refractory PTCL and will change the daily clinical practice in the treatment of PTCL. However, these are not a curative option when used as a single agent. Further clinical developments are expected, comprising 1) combination therapies of new agents with cytotoxic chemotherapies; 2) 'novel-novel' combinations; 3) immune therapies, including chimeric antigen receptor T-cell therapy; and 4) predictive marker analysis.
外周 T 细胞淋巴瘤（PTCL）是一组相对罕见的异质性成熟 T 细胞肿瘤，通常与预后不良相关，部分原因是对传统细胞毒化疗的耐药性。为了改善 PTCL 患者的预后，目前正在研究几种新型药物的临床开发。
自美国食品和药物管理局首次批准普拉曲沙（二氢叶酸还原酶抑制剂）以来，贝林司他、罗米地辛（组蛋白去乙酰化酶抑制剂）和本妥昔单抗维达汀（抗 CD30 抗体-药物偶联物）已在美国以及许多其他国家获得批准。此外，莫格利珠单抗（抗 CC 趋化因子受体 4 抗体）、西达本胺（组蛋白去乙酰化酶抑制剂）和氟达拉滨（嘌呤核苷磷酸化酶抑制剂）已在中国和日本等亚洲国家获得批准。在这篇综述中，我们总结了这些已批准药物和目前正在开发用于 PTCL 的新型药物的现有数据。
新型药物将成为复发性/难治性 PTCL 患者有希望的治疗选择，并将改变 PTCL 治疗的日常临床实践。然而，当单独使用时，这些并不是一种治愈方法。预计会有进一步的临床发展，包括 1）新型药物与细胞毒化疗联合治疗；2）“新型-新型”联合治疗；3）免疫治疗，包括嵌合抗原受体 T 细胞疗法；4）预测标志物分析。
